Opinion

Video

Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia

Author(s):

Andrew Brunner, MD,Amy DeZern, MD, MHS

Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.

Related Videos
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
Leo I. Gordon, MD
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
Related Content
Courtney DiNardo, MD, MSCE, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
October 28th 2024

Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

D. Ross Camidge, MD, PhD; Chaplain Rhonda Cooper, primary chaplain, Johns Hopkins Sidney Kimmel Cancer Center
June 13th 2024

Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy

Alex F. Herrera, MD
October 25th 2024

Nivolumab Plus AVD Prolongs PFS vs Brentuximab Vedotin Plus AVD in Advanced-Stage Hodgkin Lymphoma

Benjamin Levy, MD, clinical director, medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital; associate professor, oncology, Johns Hopkins University School of Medicine
May 30th 2024

Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC

Paula G. O’Connor, MD, chief medical officer, Nurix Therapeutics
October 22nd 2024

NX-5948 Generates Responses in R/R Waldenström Macroglobulinemia

Jorge Cortes, MD, of Georgia Cancer Center
October 21st 2024

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research